Compare TCPC & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | LXRX |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 547.4M |
| IPO Year | 2006 | 2000 |
| Metric | TCPC | LXRX |
|---|---|---|
| Price | $3.77 | $1.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.50 | ★ $4.15 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 21.28% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $3.69 | $0.32 |
| 52 Week High | $8.17 | $1.83 |
| Indicator | TCPC | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.11 | 63.66 |
| Support Level | N/A | $1.08 |
| Resistance Level | $5.99 | $1.83 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 7.54 | 73.97 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.